In vivo, two different models demonstrated that HERC5 deficiency increases the metastatic potential of NSCLC cells, suggesting that low HERC5 expression is associated with improved adaptation to metastatic sites and increased metastatic burden. This evidence concerns the gene HERC5 and non-small cell lung carcinoma.